Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ) (CALT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
calt · stock forecast · 5 analysts (3M) · FMP · updated Oct 6, 2025
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Hold
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$40.00
Consensus
$39.50
-1.3% upside
Low
$39.00
Median: $39.5 · Last Close: $40.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$39.50
-1.3% upside
High Target
$40
0.0%
Low Target
$39
-2.5%
Current Price
$40.00
as of today
Based on analyst price targets, the CALT stock price prediction for the next 12 months ranges from $39 to $40. The consensus CALT price forecast of $39.50 implies -1.3% upside from the current price of $40.00.
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CALT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-05-31 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2024-05-28 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2024-05-28 | Stifel | Downgrade ↓ | Buy→Hold |
| 2024-05-28 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-05-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-02-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-11-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-10-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Calliditas Therapeutics AB (publ) (CALT) stock. Of the recent 20 rating actions, 0 were upgrades and 4 were downgrades. 5 analysts currently cover CALT.
Analyst Recommendation Trends
CALT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2.3B
↓ 50.8% YoY
Revenue Next Year
$3.3B
↑ 46.7% YoY
EPS This Year
$-2.01
EPS Next Year
$40.08
↓ 2090.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast CALT EPS of $-2.01 for the current fiscal year, based on estimates from 1 analysts. The CALT revenue forecast is $2.3B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CALT stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CALT price target is $39.50 (-1.3% upside), with an analyst consensus of Hold.
Calliditas Therapeutics AB (publ) trades on NASDAQ under the ticker CALT. The CALT stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
CALT forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month CALT price target is $39.50, with a high forecast of $40.00 and a low of $39.00. The median price target is shown in the chart above when available. This implies -1.3% potential upside from the current price of $40.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.